Cargando…

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY

OBJECTIVE: To report the final long-term safety and efficacy analyses of patients with acromegaly treated with pegvisomant from the ACROSTUDY. DESIGN: Global (15 countries), multicentre, non-interventional study (2004–2017). METHODS: The complete ACROSTUDY cohort comprised patients with acromegaly,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Maria, Führer-Sakel, Dagmar, van der Lely, Aart J, De Marinis, Laura, Brue, Thierry, van der Lans-Bussemaker, Joli, Hey-Hadavi, Judith, Camacho-Hubner, Cecilia, Wajnrajch, Michael P, Valluri, Srinivas Rao, Palladino, Andrew Anthony, Gomez, Roy, Salvatori, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428076/ https://www.ncbi.nlm.nih.gov/pubmed/34342594 http://dx.doi.org/10.1530/EJE-21-0239

Ejemplares similares

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
por: Vila, Greisa, et al.
Publicado: (2020)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Development of ACRODAT(®), a new software medical device to assess disease activity in patients with acromegaly
por: van der Lely, Aart J., et al.
Publicado: (2017)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Pregnancy and acromegaly
por: Muhammad, Ammar, et al.
Publicado: (2016)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Towards an Earlier Diagnosis of Acromegaly and Gigantism
por: Sisco, Jill, et al.
Publicado: (2021)

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly
por: Kuker, Adriana P, et al.
Publicado: (2021)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
por: Basavilbaso, Natalia Ximena Garcia, et al.
Publicado: (2019)

ACRODAT® and AcroVoice: an insight into a holistic approach to the management of acromegaly
por: Lundie, Mark, et al.
Publicado: (2019)

Approach to the Patient With Treatment-resistant Acromegaly
por: Coopmans, Eva C, et al.
Publicado: (2022)

The position of combined medical treatment in acromegaly
por: Coopmans, Eva C., et al.
Publicado: (2019)

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
por: Moore, David J, et al.
Publicado: (2009)

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
por: Kuhn, Emmanuelle, et al.
Publicado: (2015)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells
por: Cuny, Thomas, et al.
Publicado: (2016)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series
por: Rochira, Vincenzo, et al.
Publicado: (2012)

Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience
por: Pirchio, R., et al.
Publicado: (2023)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c1go21d6gekncb20onrt4nem71